{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:02:10Z","timestamp":1792058530001,"version":"4.4.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Celecoxib is being evaluated as a chemopreventive agent. However, its mechanism of action is not clear because high doses were used for in vitro studies to obtain antitumor effects. We found that celecoxib inhibited the growth of premalignant and malignant human bronchial epithelial cells with IC50 values between 8.9 and 32.7 \u03bcmol\/L, irrespective of cyclooxygenase-2 (COX-2) expression. Normal human bronchial epithelial cells were less sensitive to celecoxib. Because these concentrations were higher than those attainable in vivo (\u22645.6 \u03bcmol\/L), we surmised that combining celecoxib with the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4HPR) might improve its efficacy. Treatment of premalignant lung cell lines with combinations of clinically relevant concentrations of celecoxib (\u22645 \u03bcmol\/L) and 4HPR (\u22640.25 \u03bcmol\/L) resulted in greater growth inhibition, apoptosis induction, and suppression of colony formation than did either agent alone. This combination also decreased the levels of Bcl-2, induced the release of mitochondrial cytochrome c, activated caspase-9 and caspase-3, and induced cleavage of poly(ADP-ribose)polymerase at concentrations at which each agent alone showed no or minimal effects. Furthermore, combinations of celecoxib and 4HPR suppressed the phosphorylation levels of serine\/threonine kinase Akt and its substrate glycogen synthase kinase-3\u03b2 more effectively than the single agents did. Accordingly, overexpression of constitutively active Akt protected bronchial epithelial cells from undergoing apoptosis after incubation with both celecoxib and 4HPR. These findings indicate that activation of the mitochondrial apoptosis pathway and suppression of the Akt survival pathway mediate the augmented apoptosis and suggest that this combination may be useful for lung cancer chemoprevention. (Cancer Res 2006; 66(19): 9762-70)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-4124","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T15:44:22Z","timestamp":1159890262000},"page":"9762-9770","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Involvement of Mitochondrial and Akt Signaling Pathways in Augmented Apoptosis Induced by a Combination of Low Doses of Celecoxib and <i>N<\/i>-(4-Hydroxyphenyl) Retinamide in Premalignant Human Bronchial Epithelial Cells"],"prefix":"10.1158","volume":"66","author":[{"given":"Claudia P.","family":"Schroeder","sequence":"first","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humam","family":"Kadara","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong K.","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waun Ki","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Lotan","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,10,3]]},"reference":[{"key":"2022061622280121100_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin\u20082005; 55: 10\u201330.","DOI":"10.3322\/canjclin.55.1.10"},{"key":"2022061622280121100_B2","doi-asserted-by":"crossref","unstructured":"Cohen V, Khuri FR. Chemoprevention of lung cancer: concepts and strategies. Expert Rev Anticancer Ther\u20082005; 5: 549\u201365.","DOI":"10.1586\/14737140.5.3.549"},{"key":"2022061622280121100_B3","doi-asserted-by":"crossref","unstructured":"Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science\u20081997; 278: 1073\u20137.","DOI":"10.1126\/science.278.5340.1073"},{"key":"2022061622280121100_B4","doi-asserted-by":"crossref","unstructured":"Muscat JE, Chen SQ, Richie JP, Jr., et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer\u20082003; 97: 1732\u20136.","DOI":"10.1002\/cncr.11242"},{"key":"2022061622280121100_B5","doi-asserted-by":"crossref","unstructured":"Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol\u20082005; 23: 3186\u201397.","DOI":"10.1200\/JCO.2005.14.209"},{"key":"2022061622280121100_B6","doi-asserted-by":"crossref","unstructured":"Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets\u20082004; 4: 29\u201342.","DOI":"10.2174\/1568009043481632"},{"key":"2022061622280121100_B7","doi-asserted-by":"crossref","unstructured":"Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene\u20081999; 18: 7908\u201316.","DOI":"10.1038\/sj.onc.1203286"},{"key":"2022061622280121100_B8","unstructured":"Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res\u20082001; 7: 861\u20137."},{"key":"2022061622280121100_B9","unstructured":"Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res\u20081998; 58: 3761\u20134."},{"key":"2022061622280121100_B10","doi-asserted-by":"crossref","unstructured":"Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med\u20082000; 342: 1946\u201352.","DOI":"10.1056\/NEJM200006293422603"},{"key":"2022061622280121100_B11","doi-asserted-by":"crossref","unstructured":"Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol\u20082004; 2: 880\u20137.","DOI":"10.1016\/S1542-3565(04)00389-1"},{"key":"2022061622280121100_B12","unstructured":"Reddy BS, Hirose Y, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res\u20082000; 60: 293\u20137."},{"key":"2022061622280121100_B13","doi-asserted-by":"crossref","unstructured":"Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut\u20082004; 53: 195\u2013200.","DOI":"10.1136\/gut.2003.021477"},{"key":"2022061622280121100_B14","doi-asserted-by":"crossref","unstructured":"Diperna CA, Bart RD, Sievers EM, Ma Y, Starnes VA, Bremner RM. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg\u20082003; 126: 1129\u201333.","DOI":"10.1016\/S0022-5223(03)00790-6"},{"key":"2022061622280121100_B15","doi-asserted-by":"crossref","unstructured":"Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer\u20082006; 12: 6\u20139.","DOI":"10.1186\/1471-2407-6-9"},{"key":"2022061622280121100_B16","unstructured":"Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res\u20082000; 60: 2101\u20133."},{"key":"2022061622280121100_B17","doi-asserted-by":"crossref","unstructured":"Li N, Sood S, Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res\u20082005; 11: 2089\u201396.","DOI":"10.1158\/1078-0432.CCR-04-1684"},{"key":"2022061622280121100_B18","doi-asserted-by":"crossref","unstructured":"Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res\u20082004; 64: 3334\u201343.","DOI":"10.1158\/0008-5472.CAN-03-2422"},{"key":"2022061622280121100_B19","unstructured":"Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res\u20082000; 60: 5599\u2013602."},{"key":"2022061622280121100_B20","doi-asserted-by":"crossref","unstructured":"Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog\u20081999; 25: 231\u201340.","DOI":"10.1002\/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F"},{"key":"2022061622280121100_B21","doi-asserted-by":"crossref","unstructured":"Mao JT, Cui X, Reckamp K, et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer\u20082005; 7: 30\u20139.","DOI":"10.3816\/CLC.2005.n.019"},{"key":"2022061622280121100_B22","doi-asserted-by":"crossref","unstructured":"Abou-Issa H, Alshafie G. Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther\u20082004; 4: 725\u201334.","DOI":"10.1586\/14737140.4.5.725"},{"key":"2022061622280121100_B23","doi-asserted-by":"crossref","unstructured":"Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-\u03baB. FASEB J\u20082001; 15: 1622\u20134.","DOI":"10.1096\/fj.00-0716fje"},{"key":"2022061622280121100_B24","doi-asserted-by":"crossref","unstructured":"Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther\u20082004; 3: 847\u201352.","DOI":"10.4161\/cbt.3.9.1037"},{"key":"2022061622280121100_B25","doi-asserted-by":"crossref","unstructured":"Sun SY, Schroeder CP, Yue P, Lotan D, Hong WK, Lotan R. Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther\u20082005; 4: 407\u201313.","DOI":"10.4161\/cbt.4.4.1618"},{"key":"2022061622280121100_B26","doi-asserted-by":"crossref","unstructured":"Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R. Implication of mitochondria-derived reactive oxygen species, cytochrome c and caspase-3 in N-(4 hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene\u20081999; 18: 6380\u20137.","DOI":"10.1038\/sj.onc.1203024"},{"key":"2022061622280121100_B27","unstructured":"Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res\u20081998; 4: 1345\u201355."},{"key":"2022061622280121100_B28","doi-asserted-by":"crossref","unstructured":"Sun SY, Hail N, Jr., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst\u20082004; 96: 662\u201372.","DOI":"10.1093\/jnci\/djh123"},{"key":"2022061622280121100_B29","doi-asserted-by":"crossref","unstructured":"Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al. Preliminary results on safety and activity of a randomized, double-blind, 2 \u00d7 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol\u20082006; 24: 129\u201335.","DOI":"10.1200\/JCO.2005.02.9934"},{"key":"2022061622280121100_B30","doi-asserted-by":"crossref","unstructured":"Klein-Szanto AJ, Iizasa T, Momiki S, et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci U S A\u20081992; 89: 6693\u20137.","DOI":"10.1073\/pnas.89.15.6693"},{"key":"2022061622280121100_B31","unstructured":"Reddel RR, Ke Y, Gerwin BI, et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res\u20081988; 48: 1904\u20139."},{"key":"2022061622280121100_B32","doi-asserted-by":"crossref","unstructured":"Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst\u20081990; 82: 1107\u201312.","DOI":"10.1093\/jnci\/82.13.1107"},{"key":"2022061622280121100_B33","doi-asserted-by":"crossref","unstructured":"Li X, Traganos F, Melamed MR, Darzynkiewicz Z. Single-step procedure for labeling DNA strand breaks with fluorescein-or BODIPY-conjugated deoxynucleotides: detection of apoptosis and bromodeoxyuridine incorporation. Cytometry\u20081995; 20: 172\u201380.","DOI":"10.1002\/cyto.990200210"},{"key":"2022061622280121100_B34","doi-asserted-by":"crossref","unstructured":"Chun KH, Kosmeder JW, Sun S, et al. Chemopreventive effects of deguelin, a naturally occurring PI3K\/Akt inhibitor, during the malignant transformation of human bronchial epithelial cells. J Natl Cancer Inst\u20082003; 95: 291\u2013302.","DOI":"10.1093\/jnci\/95.4.291"},{"key":"2022061622280121100_B35","unstructured":"Ji L, Nishizaki M, Gao B, Burbee D, et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res\u20082002; 62: 2715\u201320."},{"key":"2022061622280121100_B36","doi-asserted-by":"crossref","unstructured":"Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt protooncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell\u20081995; 81: 727\u201336.","DOI":"10.1016\/0092-8674(95)90534-0"},{"key":"2022061622280121100_B37","doi-asserted-by":"crossref","unstructured":"Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev\u20082004; 13: 920\u20137.","DOI":"10.1158\/1055-9965.920.13.6"},{"key":"2022061622280121100_B38","unstructured":"Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res\u20082003; 9: 2032\u20139."},{"key":"2022061622280121100_B39","doi-asserted-by":"crossref","unstructured":"Hiroshima K, Iyoda A, Shibuya K, et al. Evidence of neoangiogenesis and an increase in the number of proliferating cells within the bronchial epithelium of smokers. Cancer\u20082002; 95: 1539\u201345.","DOI":"10.1002\/cncr.10850"},{"key":"2022061622280121100_B40","doi-asserted-by":"crossref","unstructured":"Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res\u20082005; 11: 2074\u201382.","DOI":"10.1158\/1078-0432.CCR-04-1376"},{"key":"2022061622280121100_B41","doi-asserted-by":"crossref","unstructured":"Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res\u20082004; 64: 9027\u201334.","DOI":"10.1158\/0008-5472.CAN-04-3703"},{"key":"2022061622280121100_B42","doi-asserted-by":"crossref","unstructured":"Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology\u20082004; 39: 1028\u201337.","DOI":"10.1002\/hep.20143"},{"key":"2022061622280121100_B43","doi-asserted-by":"crossref","unstructured":"Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J\u20082003; 17: 1547\u20139.","DOI":"10.1096\/fj.02-0947fje"},{"key":"2022061622280121100_B44","doi-asserted-by":"crossref","unstructured":"Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem\u20082000; 275: 11397\u2013403.","DOI":"10.1074\/jbc.275.15.11397"},{"key":"2022061622280121100_B45","doi-asserted-by":"crossref","unstructured":"Delia D, Aiello A, Formelli F, et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood\u20081995; 85: 359\u201367.","DOI":"10.1182\/blood.V85.2.359.bloodjournal852359"},{"key":"2022061622280121100_B46","doi-asserted-by":"crossref","unstructured":"Boya P, Morales MC, Gonzalez-Polo RA, et al. The chemopreventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene\u20082003; 22: 6220\u201330.","DOI":"10.1038\/sj.onc.1206827"},{"key":"2022061622280121100_B47","doi-asserted-by":"crossref","unstructured":"Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol\u20082004; 22: 4217\u201326.","DOI":"10.1200\/JCO.2004.01.103"},{"key":"2022061622280121100_B48","doi-asserted-by":"crossref","unstructured":"Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology\u20082003; 38: 756\u201368.","DOI":"10.1053\/jhep.2003.50380"},{"key":"2022061622280121100_B49","doi-asserted-by":"crossref","unstructured":"Arico S, Pattingre S, Bauvy C, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem\u20082002; 277: 27613\u201321.","DOI":"10.1074\/jbc.M201119200"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/19\/9762\/2554989\/9762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/19\/9762\/2554989\/9762.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:45:07Z","timestamp":1655430307000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/19\/9762\/526308\/Involvement-of-Mitochondrial-and-Akt-Signaling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":49,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2006,10,3]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-4124","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,1]]}}}